Created in May 2018, Zionexa is an international company developing and commercializing Molecular Imaging Companion Diagnostics (CDx) for targeted therapies in Oncology aimed to improve patients’ pathway and quality of life.
Zionexa is a spin-off of Cyclopharma, a radiopharmaceutical company producing and commercializing biomarkers in France.
We develop Molecular Imaging CDx for targeted therapies that will transform oncology by improving the patient’s pathway and quality of life. Within a PET Scan (Positron Emission Tomography) exam, biomarkers help Oncologists and Nuclear Medicine Physicians to personalize the treatment, based on the localization and characteristics of the tumors.
Meet our team of experts in CDx Imaging for Oncology:
Bernard Landes
Chairman & CEO
- Former General Manager of Cyclopharma
-
25 years of experience in pharmaceutical industry and IT
Peter Webner
CEO, US
- Former General Manager of Zevacor Pharma
-
25 years of experience in radiopharmaceutical industry
Jean-Bernard Deloye
Head of Market Access
- Former Deputy General Manager of Cyclopharma
-
25 years of experience in radiopharmaceutical industry
Yann Bouvet
Head of R&D
- Former Pharmaceutical and Industrial Development Director of Cyclopharma
-
10 years of experience in R&D projects
Jean-Bernard Deloye
Head of Market Access
- Former Deputy General Manager of Cyclopharma
-
25 years of experience in radiopharmaceutical industry
Yann Bouvet
Head of R&D
- Former Pharmaceutical and Inustrial Development Director of Cyclopharma
-
10 years of experience in R&D projects
Jerome Francillard
CFO
- Former CFO of Energy Pool
- 15 years of experience in consulting and financing growth
Together, we are dedicated to
Privacy Policy
